Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used... 5-FU is widely used in the U.S. and is often first or second line therapy for a variety of cancers including colorectal, breast, gastric, head and neck, ovarian and basal cell cancer of the skin.
- Mechanism
- Curator reviewed
Normally, 5-FU is rapidly broken down in the body by an enzyme known as dihydropyrimidine dehydrogenase (DPD). Eniluracil irreversibly inhibits DPD, thereby substantially slowing the breakdown of 5-FU and prolonging exposure of the tumor cells to the drug.
- Primary indication
- For the treatment of cancer in combination with 5-fluorouracil.Curator reviewed
- Formula / weight
- C6H4N2O2 · 136.1082 g/mol (avg)
- Also known as
- 5-Ethynyluracil
- Code names
- 776C85 · Compound 776C · GW776C85 · PCS6422
Resolves to
JOZGNYDSEBIJDH-UHFFFAOYSA-NSMILESO=C1NC=C(C#C)C(=O)N1What you can answer from here — as of September 20, 2026
Which drugs share a target with Eniluracil, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account